Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2014

View Archived Issues

Validation of PIM-1 inhibition as a treatment for KRas-driven NSCLC in mice

Spinal GlyT2 modulates spinal cord injury-induced spasticity in a rat model

Researchers find common genetic variant associated with cervical artery dissection

Anti-PD-L1 antibody efficacious against metastatic bladder cancer

Veliparib granted FDA orphan drug status

EB Pharma in-licenses Janssen farnesyl transferase inhibitor for HDV

FDA grants orphan drug status to OTL-38 for detecting ovarian cancer

Biotie Therapies begins phase IIa trial of SYN-120 in Parkinson's disease dementia

Dosing begins in phase I study of Kinex's KX2-361

Data presented on a novel MAPK pathway inhibitor for the treatment of colorectal cancer

Novastem treats first patient using mesenchymal and neural stem cell combination

Medtronic submits premarket approval application for SynchroMed II

Spectrum Pharmaceuticals submits NDA to FDA for Captisol-Enabled Melphalan

Corgenix Medical receives grants to support Ebola rapid test development

Determination of exosomal miRNAs as markers of multiple myeloma prognosis

Jiangsu Hengrui Medicine describes bisulfate salt of JAK inhibitor for rheumatoid arthritis

Researchers patent IL-1beta/IRAP chimeric proteins for inflammation

Janssen and Gilead amend and expand HIV single-tablet regimen development agreements

Alexion completes rolling BLA submission to the FDA for asfotase alfa

FDA approves Dyloject for pain management

EIT+ patents glycoconjugates for use as pertussis vaccines

University of Leicester patents cytolysin inhibitors

Bayer Schering Pharma describes TTK inhibitors

Nanjing Sanhome Pharmaceutical prepares anti-HCV nucleosides

VEGFR-2 inhibitors reported in Kala Pharmaceuticals patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...